Form 8-K - Current report:
SEC Accession No. 0001213900-25-049451
Filing Date
2025-05-30
Accepted
2025-05-30 16:01:23
Documents
12
Period of Report
2025-05-23
Items
Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea0243908-8k_adial.htm   iXBRL 8-K 25666
  Complete submission text file 0001213900-25-049451.txt   190627

Data Files

Seq Description Document Type Size
2 XBRL SCHEMA FILE adil-20250523.xsd EX-101.SCH 3005
3 XBRL LABEL FILE adil-20250523_lab.xml EX-101.LAB 34239
4 XBRL PRESENTATION FILE adil-20250523_pre.xml EX-101.PRE 22352
14 EXTRACTED XBRL INSTANCE DOCUMENT ea0243908-8k_adial_htm.xml XML 3657
Mailing Address 1180 SEMINOLE TRAIL SUITE 495 CHARLOTTESVILLE VA 22901
Business Address 1180 SEMINOLE TRAIL SUITE 495 CHARLOTTESVILLE VA 22901 434-422-9800
ADIAL PHARMACEUTICALS, INC. (Filer) CIK: 0001513525 (see all company filings)

EIN.: 800667150 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38323 | Film No.: 251010674
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)